In the presentation, titled “KROS 101: A Next Generation GITR agonist boosting anti-tumor T cell responses and reprogramming the tumor environment,” study authors demonstrated that KROS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback